Genmab (GMAB)
(Delayed Data from NSDQ)
$28.00 USD
-1.34 (-4.57%)
Updated May 24, 2024 04:00 PM ET
After-Market: $28.00 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Brokerage Reports
Genmab A/S Sponsored ADR [GMAB]
Reports for Purchase
Showing records 41 - 60 ( 110 total )
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX Wins Recommendation From Key UK Institute; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX 2021 Net Sales Announced; Upgrading to Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Synaffix Agreement Provides Disruptive Antibody Technologies; Reit. Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Epcoritamab Shines at ASH, But We Await Further Data; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
SITC Takeaways; 3Q21 Financials; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Tisotumab Receives FDA Accelerated Approval in 2L+ Cervical Cancer; Reit Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Tisotumab and RYBREVANT Updates from ESMO; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Stepping to Sidelines After Profitable Run Up; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX 2Q21 Sales Beats Street Consensus; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
FDA Greenlights Another DARZALEX Faspro Combo Regimen; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX SC Receives Two E.U. Approvals; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Kesimpta Long-Term Safety Data Bolster Value Proposition; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Numerous ASCO and EHA Updates Underscore Portfolio Power; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX SC Receives Positive CHMP Opinions; Rybrevant FDA Approval; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Top- and Bottom-Line Beat; 1Q21 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Tisotumab Vedotin Submission Accepted; AACR Data Overview; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Kesimpta Approved in Europe; DARZALEX Competitor Update; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
2020 Financial Results Reported; Modulating PT to $47
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Tisotumab Vedotin Submitted to FDA for Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R